Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 15/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818632 | 1.00 | PLAU (0.41) | PLAUMALT1HTTKMT2ADYRK1A | |
| SCHEMBL23608899 | 0.80 | MALT1 (0.45) | MALT1 | |
| SCHEMBL25367079 | 0.76 | S1PR1 (0.38) | MALT1HTTKMT2ADYRK1AS1PR1 | |
| SCHEMBL31268113 | 0.76 | S1PR1 (0.38) | MALT1HTTKMT2ADYRK1AS1PR1 | |
| SCHEMBL30517100 | 0.76 | MALT1 (0.39) | MALT1 | |
| SCHEMBL17292960 | 0.76 | MALT1 (0.39) | MALT1 | |
| SCHEMBL25419609 | 0.72 | MALT1 (0.35) | MALT1HTTKMT2ADYRK1A | |
| SCHEMBL17292925 | 0.72 | DYRK1A (0.31) | HTTKMT2ADYRK1A | |
| SCHEMBL21030633 | 0.72 | MALT1 (0.44) | MALT1 | |
| SCHEMBL22758182 | 0.72 | MALT1 (0.39) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024020534-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-115677667-A | Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent | 海创药业股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2022164789-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS | SCHRÖDINGER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | PLAU 2826/4885MALT1 1/4885HTT 3272/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | PLAU 4407/4885MALT1 3/4885HTT 2638/4885 |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | AR, ADRM1, MDM2 | PLAU 722/4885MALT1 340/4885HTT 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.